Quarterly ResultMay 5, 2026, 04:12 PM
Cytokinetics Q1 Net Loss $206M; MYQORZO Launch Strong; ACACIA-HCM Positive
AI Summary
Cytokinetics reported its first quarter 2026 financial results, with total revenues significantly increasing to $19.4 million, including $4.8 million in net product revenue from the strong initial U.S. launch of MYQORZO. Despite a widened net loss of $206.0 million, the company highlighted robust demand for MYQORZO, with over 680 patients prescribed the drug. Additionally, positive topline results from the ACACIA-HCM trial for non-obstructive HCM were announced, and MYQORZO received European Commission approval, expanding its market potential.
Key Highlights
- MYQORZO net product revenue was $4.8 million for its initial partial quarter.
- Total revenues increased to $19.4 million in Q1 2026 from $1.6 million in Q1 2025.
- Net loss widened to $206.0 million, or $(1.67) per share, compared to $161.4 million, or $(1.36) per share, in Q1 2025.
- Cash, cash equivalents, and investments totaled approximately $1.1 billion as of March 31, 2026.
- MYQORZO was prescribed to an estimated 680 patients by over 275 unique healthcare providers in Q1.
- ACACIA-HCM pivotal Phase 3 trial met dual primary endpoints for non-obstructive HCM.
- MYQORZO received approval from the European Commission for symptomatic obstructive HCM.
- MAPLE-HCM Supplemental NDA accepted by FDA with PDUFA date of November 14, 2026.